Werewolf sells pre-clinical INDUCER and INDUKINE platforms to EMD Serono for $28M upfront plus $5M

Werewolf Therapeutics, Inc.

Closed Aug 14, 2026 asset sale to EMD Serono: $28M upfront plus $5M upon transfer completion.
Sale covers pre-clinical INDUCER and INDUKINE platforms; excludes WTX-124 and WTX-330 clinical programs.
Company retains rights to advance WTX-124 and WTX-330; EMD grants exclusive license to related patents.
License agreement enables sublicenses to Harpoon and Jazz under existing agreements; 24-month non-compete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.